theleaflet

One Year of Treatment, Then Nothing: Indias rare disease policy and why patients are left to fight alone

India's rare disease policy sets a Rs. 50 lakh ceiling. Roche's Risdiplam costs Rs. 72 lakhs a year. A generic alternative exists at a fraction of the price, but is tied up in patent litigation. Amidst this, rare disease patients are left to fight their own battles.